cyclophosphamide + vincristine + prednisone + bleomycin + doxorubicin + methotrexate

This regimen is a **combination chemotherapy protocol** composed of six cytotoxic agents: **cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and methotrexate**. The most recognized form of this regimen is known as **MACOP-B**. Developed in the early 1980s, MACOP-B emphasizes intensive, short-duration treatment for **aggressive non-Hodgkin lymphoma (primarily diffuse large-cell lymphoma)**[6]. Each agent contributes a distinct mechanism of action: cyclophosphamide (an alkylating agent), vincristine (a microtubule inhibitor), prednisone (a synthetic glucocorticoid), bleomycin (induces DNA strand breaks), doxorubicin (an anthracycline DNA intercalator and topoisomerase II inhibitor), and methotrexate (an antimetabolite inhibiting dihydrofolate reductase)[6]. The regimen aims for high complete remission rates with a relatively short, intensive course of therapy compared to earlier, more prolonged regimens[6][5]. It is not a proprietary formulation but rather a protocol used by oncology centers.

Other names

MACOP-Bm-BACOD